EZH2 and lung adenocarcinoma: Further analysis showed that 357 cases of lung adenocarcinoma with EZH2 high expression had a median survival time of 90 months and 360 cases with EZH2 with low expression had a median survival time of 119.87 months (HR = 1.27and 95% CI 1.01−1.6; p < 0.05) (Figure 3(b)).